Yashveer Bhardwaj’s Post

Congratulations to Barinthus Biotherapeutics: the Life Sciences & Health Tech Company of the Year! 🥼🏆 Sponsored by Freeths, this award was presented to tonight’s incredible winner based on it having demonstrated sustained innovation and commercial success for several years. Freeths specifically noted that ‘to support the development of its programs, Barinthus has established partnerships with leading institutions worldwide. With a powerful suite of innovative technologies, Barinthus aims to create more effective immunotherapies for the treatment of infectious diseases, cancer, and autoimmunity.’ The Thames Valley’s most impressive clinical-stage biopharmaceutical company, Barinthus Biotherapeutics is driven by a genuine passion for science and a dedication to strength and resilience in its processes. The company is keenly focused on moving science forward, proudly embracing the values and technological approach that continue to be the hallmark and fabric of its business. For more information, click here: https://lnkd.in/eYhymmzA #TVTIA24 #technology #innovation #science #awards #health #healthtech #businessnews #businessintelligence

💊 Big News in Biotech! Eli Lilly and Company Acquires Morphic Holding for $3.2 Billion 🚀 Just yesterday, Eli Lilly announced its latest move to acquire Morphic Holding. This marks a significant leap in their immunology pipeline, targeting Crohn’s disease and ulcerative colitis. Key Takeaways for Family Offices: 🔬 Strategic Growth: This acquisition expands Eli Lilly's portfolio in immunology, addressing critical unmet medical needs and positioning them at the forefront of biotech innovation. 📊 Valuation Confidence: Paying a 79% premium over Morphic’s closing price highlights Eli Lilly's strong belief in Morphic’s potential to revolutionize treatment options. 💡 Investment Insights: Notably, in February 2024, Bloomberg reported that the Walton and Soros Family Offices had boosted their biotech holdings. The Soros Management Fund purchased a $19.2M stake in Eli Lilly in Q4 2023. 🌍 Market Potential: The global market for inflammatory bowel disease treatments is projected to soar from $29.57 billion in 2024 to $44.08 billion by 2032 (Grand View Research, Inc.). Family offices can draw inspiration from Eli Lilly’s strategic playbook, leveraging their resources to back innovative biotech firms and drive breakthroughs in healthcare. 🔗 Dive deeper into the story here: https://lnkd.in/eB842D92 #FamilyOffices #FamilyOffice #UHNWI #Investment #Biotech #strategicacquisition #Healthcare #LLY #MORF #medicine #Finance

🌐 Unlock the Future of #RespiratoryCare with DelveInsight Business Research LLP's Latest Report! DelveInsight Business Research LLP’s comprehensive Idiopathic Pulmonary Fibrosis Market report offers critical insights into market dynamics, emerging therapies, prevalence, and trends shaping the landscape. Discover opportunities driving innovation and how the pipeline is evolving to address unmet needs. The leading #IdiopathicPulmonaryFibrosisCompanies such as FibroGen, Inc., Hoffmann-La Roche Ltd, United Therapeutics Corporation, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto, Inc. Biotech, Horizon, CSL Behring, Kadmon, a Sanofi Company, LLCs, MediciNova, Inc., PureTech Health, Bristol Myers Squibb Nitto Denko Corporation, Vicore Pharma AB and others. 🚀 Stay ahead in the IPF market with in-depth analysis and projections! Explore Report Now @ https://lnkd.in/dp5MC-_T #IdiopathicPulmonaryFibrosis #IPFMarket #MarketResearch #PharmaInsights #DelveInsight

🚀 Every drug has a unique story, and Keytruda’s journey is particularly remarkable. 💊✨Keytruda (Pembrolizumab) has become the world’s top-selling drug, achieving an impressive $25 billion in sales in 2023. Its path from discovery to clinical trials and market dominance offers a masterclass in successful drug development. 📍 Key Highlights of Keytruda's Success: 1️⃣ Staggering Revenue: Reached $25 billion, accounting for about 42% of Merck's total revenue. 2️⃣ Serendipitous Discovery: Its discovery was an unexpected but fortuitous event. 3️⃣ Competitive Drive: Pressure from Bristol-Myers Squibb inspired Merck to aggressively push Keytruda in the market. 4️⃣ Strategic Investment: With significant financial backing, Merck utilized three years to continually update clinical data and execute a robust global marketing strategy focused on patient needs. 5️⃣ Collaborative Efforts: Partnerships and combination therapies have extended Keytruda's impact and longevity. 💡 While the discovery of a drug can be serendipitous, building a blockbuster like Keytruda requires strategic financial support and insightful clinical development. We provide a one-page cheatsheet to help you know the story of Keytruda. For details, please find it https://lnkd.in/g8jBQPXk 💊✨#Every drug tells a story #DrugWonder #Merck #Forbes #Oncology #Immunotherapy #FierceBiotech #Nature Reviews Drug Discovery

We are transforming the future of biopharma. Discover the Power of SDC - https://lnkd.in/ghruHFDE. Synkrino Development Company partners with biotech to finance and develop innovative high impact therapeutics programs. We serve the entire pharma ecosystem of patients, prescribers, payers, biotechs, and pharma companies by financing, accelerating, and pushing forward drug candidates with the potential to significantly improve the standard of care – offering a new range of therapeutic options that balance price and treatment outcome. Our process creates portfolios of orthogonal assets (biological target, disease indication, modality) with the aim of de-risking biotech investments for institutional investors. We partner with biotech on an asset basis – not a company basis – creating a stream of uncorrelated cash flows with a superior return-on-investment profile. https://synkrino.dev

🔬 𝗘𝘅𝗽𝗹𝗼𝗿𝗶𝗻𝗴 𝘁𝗵𝗲 𝗔𝗻𝘁𝗶𝗯𝗼𝗱𝘆-𝗗𝗿𝘂𝗴 𝗖𝗼𝗻𝗷𝘂𝗴𝗮𝘁𝗲 (𝗔𝗗𝗖) 𝗟𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲 The ADC landscape is evolving rapidly, with numerous companies advancing their ADC programs through various stages of development. This comprehensive graphic breaks down the highest stage of development by company and payload, highlighting key players and their progress. 𝗞𝗲𝘆 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀 👇 𝗧𝘂𝗯𝘂𝗹𝗶𝗻 𝗜𝗻𝗵𝗶𝗯𝗶𝘁𝗼𝗿𝘀: Notable advancements from Sanofi, Genmab, and Roche. 𝗗𝗡𝗔-𝗗𝗮𝗺𝗮𝗴𝗶𝗻𝗴 𝗔𝗴𝗲𝗻𝘁𝘀: Strong pipeline from Gilead Sciences, Pfizer, and AstraZeneca. 𝗡𝗼𝘃𝗲𝗹 𝗔𝗽𝗽𝗿𝗼𝗮𝗰𝗵𝗲𝘀/𝗨𝗻𝗱𝗶𝘀𝗰𝗹𝗼𝘀𝗲𝗱: Innovative strategies emerging from Rakuten Medical and AstraZeneca. 𝗗𝗲𝘃𝗲𝗹𝗼𝗽𝗺𝗲𝗻𝘁 𝗦𝘁𝗮𝗴𝗲𝘀: 𝗣𝗵𝗮𝘀𝗲 𝟭 & 𝟭/𝟮: Early-stage breakthroughs from various biotech firms. 𝗣𝗵𝗮𝘀𝗲 𝟮: Promising candidates progressing through clinical trials. 𝗣𝗵𝗮𝘀𝗲 𝟯/𝗥𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆: Late-stage therapies nearing market approval. 𝗔𝗽𝗽𝗿𝗼𝘃𝗲𝗱:Market-ready ADCs already transforming patient care. Curated by Andrew Pannu and powered by Sleuth Insights, this visual map provides a snapshot of the dynamic ADC landscape, underscoring the potential of these therapies to revolutionize cancer treatment. What are your thoughts on the next big breakthrough in ADCs? Let's discuss! #Biotech #ADC #CancerResearch #Innovation #Healthcare #Pharmaceuticals #DrugDevelopment

On #WorldAlzheimersDay, we reflected on the urgency of finding solutions for this devastating disease. At InVivo Biosystems, we are proud to play a part in the ongoing fight against Alzheimer’s through our innovative RapidGen™ preclinical platform. RapidGen™ revolutionizes drug discovery by starting with AI-powered target selection, followed by the use of validated, humanized Alzheimer's Disease models and high-throughput phenotypic screening. This streamlined process accelerates the delivery of IND-enabling data, empowering pharmaceutical companies to make faster, more informed decisions—advancing potential treatments to the clinic without added financial strain. Learn more about how the RapidGen™ platform is accelerating preclinical development here: https://lnkd.in/gUH88Jbp #AlzheimersDisease #PreclinicalResearch #InVivoBiosystems #DrugDiscovery #DrugDevelopment #Innovation #BiotechInnovation #NeurodegenerativeDisease

New Case Study: At Adnexi, we just helped a biopharmaceutical company identify and fully profile key scientific experts for 10 different cancer types to engage in Medical Affairs strategies! A few highlights of this meaningful project: - We processed massive structured and unstructured data to identify, profile and rank key experts in various tumor types - We enabled the creation of meaningful segments using our new features on the platform - We helped make the information portable and always updating, so that the company can bring fresh profiles to their next meeting and congress. If you have similar strategic goals to find, segment and engage key external experts, we can help - using the latest technology. Email: sandra@adnexi.com #medicalaffairs #kol #keyexternalexperts #keyopinionleaders #scientificaffairs #clinicaltrials

Really interested to see how AstraZeneca will achieve these ambitious goals of delivering $80bn in annual revenue by 2030! Just for context: - 75% higher than what it raked in last year at $45.8 billion - More than 8% YoY growth will need to be acheived (GSK, Johnson & Johnson & Novartis aiming for 5-7%) - Patent Expiration - Farxiga, Lynparza, Tagrisso and Calquence - Restructuring across their #UK sites With more than 170 programs in its pipeline and potentially more acquisitions on the horizon, will we be standing here in 2030 celebrating with AZ? #Pharmaceutical #Growth #Biotech

🎗️💊 With a solid commitment to innovation, #Bluepharma has evolved from providing generic medicines to becoming a key player in advanced and complex therapeutics. Recognised globally, the company operates in over 40 countries and recently inaugurated one of Europe's largest oncology manufacturing units in Coimbra. 🏭 📈 Bluepharma's strategic focus on oncology and high-tech injectables highlights its role in shaping cutting-edge therapeutic solutions. With 87% of its exports, the company targets robust growth in international markets like the United States. 🌍 🧪 In line with its mission to revolutionise healthcare, Bluepharma has partnered with academia and invested in Coimbra Life Sciences Park and CInTech to establish Portugal's first technology centre for complex injectables. These efforts underline its dedication to innovation and global healthcare excellence. 🔗 Read the full article here ⬇ https://lnkd.in/d5PZGMzg #Innovation #Medine #PharmaceuticalIndustry #MadeInPortugal #BuyFromPortugal #InvestInPortugal #BusinessMatchMaking #PortugalOpenForBusiness #AICEP